This content is intended for healthcare professionals only Learn More: Pregnancy and Lactation Studies Completed Certolizumab Pegol Studies About the CRIB Study CRIB was a pharmacokinetic study. Evaluating the safety of certolizumab pegol (CZP) was one of the aims on top of assessing the potential level of placental transfer of CZP from pregnant women to their infants. This study followed sixteen women who were at least 30 weeks into their gestation and were already receiving CZP at approved doses.Click here to access the full study publicationClick here to access a plain language summary About the CRADLE Study CRADLE was a pharmacokinetic study. Evaluating the safety of certolizumab pegol (CZP) was one of the aims on top of determining the concentration of CZP in human breast milk and estimating the average daily infant dose, which is the daily dose of maternal CZP ingested by the breastfeeding infant.Click here to access the full study publicationClick here to access a plain language summary About the CHERISH Study The CHERISH study aimed to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies, and safety of CZP throughout pregnancy in participants with chronic inflammatory diseases.Click here to access pharmacokinetic data from the CHERISH study presented at EULAR 2024Click here to access a plain language summary About the IMPACT Study The IMPACT study aimed to evaluate whether adding certolizumab pegol to standard therapy could improve pregnancy outcomes in women with antiphospholipid syndrome and persistent lupus anticoagulant positivity, alongside assessing its impact on placental function and markers of adverse pregnancy outcomes.Click here to access the full study publication Ongoing Bimekizumab (Bimzelx®▼) Studies About the BE CARING Study The BE CARING study is a trial designed to measure the concentration of bimekizumab (Bimzelx®) in mature human breast milk from mothers receiving the treatment for inflammatory conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa. The study aims to inform understanding of infant exposure during breastfeeding.Click here to access full study information About the MotherToBaby Pregnancy Registry MotherToBaby Pregnancy Registry is enrolling people who are pregnant and have taken bimekizumab (Bimzelx®) during pregnancy to better understand its effects when used to treat conditions such as psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. The study aims to generate more information on medication safety for pregnant people and their babies by collecting real-world data on Bimzelx® exposure in pregnancy.Click here to access full study information ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
